PBYI实时信号 | 通过Getagraph.com最大化利润

购买 107278 min ago

@ $7.35

发出时间: 15 Feb 2024 @ 04:31

回报率: -31.70%

上一信号: Feb 14 - 04:35

上一信号: 出售

回报率: 18.17 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally...

Stats
今日成交量	167 402
平均成交量	578 890
市值	242.00M
EPS	$0 ( 2024-02-29 )
下一个收益日期	( $-0.160 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	11.16
ATR14	$0.0100 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Auerbach Alan H	Buy	6 577	Common Stock
2024-03-15	Auerbach Alan H	Buy	9 047	Stock Option (Right to Buy)
2024-02-12	Wong Alvin F	Buy	43 307	Common Stock
2024-02-12	Wong Alvin F	Buy	59 946	Stock Option (Right to Buy)
2024-02-12	Nougues Maximo F	Buy	43 307	Common Stock

INSIDER POWER
69.66
Last 99 transactions
Buy: 2 879 886 \| Sell: 561 464

音量相关性

長: -0.17 (neutral)

短: -0.69 (moderate negative)

Signal:(45.182) Neutral

Puma Biotechnology Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Puma Biotechnology Inc 相关性 - 货币/商品

-0.09
( neutral )

0.35
( neutral )

0.00
( neutral )

0.61
( weak )

0.29
( neutral )

Puma Biotechnology Inc 财务报表

Annual	2023
营收:	$235.64M
毛利润:	$172.96M (73.40 %)
EPS:	$0.460

FY	2023
营收:	$235.64M
毛利润:	$172.96M (73.40 %)
EPS:	$0.460

FY	2022
营收:	$228.00M
毛利润:	$172.90M (75.83 %)
EPS:	$0.0204

FY	2021
营收:	$253.16M
毛利润:	$189.45M (74.84 %)
EPS:	$-0.720

Financial Reports:

No articles found.

Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

实时更新： Puma Biotechnology Inc [PBYI]

Upcoming Earnings Alert